These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

899 related articles for article (PubMed ID: 27769868)

  • 1. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease.
    Jiang T; Sun Q; Chen S
    Prog Neurobiol; 2016 Dec; 147():1-19. PubMed ID: 27769868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
    Beal MF
    J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease.
    Ganguly G; Chakrabarti S; Chatterjee U; Saso L
    Drug Des Devel Ther; 2017; 11():797-810. PubMed ID: 28352155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic strategy for Parkinson's and Alzheimer's disease.
    Esposito E; Cuzzocrea S
    Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and neurodegenerative diseases: looking for a therapeutic solution inspired on benzopyran chemistry.
    Gaspar A; Milhazes N; Santana L; Uriarte E; Borges F; Matos MJ
    Curr Top Med Chem; 2015; 15(5):432-45. PubMed ID: 25658803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress.
    Perluigi M; Joshi G; Sultana R; Calabrese V; De Marco C; Coccia R; Butterfield DA
    Neuroscience; 2006; 138(4):1161-70. PubMed ID: 16427207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders.
    van Muiswinkel FL; Kuiperij HB
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):267-81. PubMed ID: 15975029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mangiferin: A multipotent natural product preventing neurodegeneration in Alzheimer's and Parkinson's disease models.
    Feng ST; Wang ZZ; Yuan YH; Sun HM; Chen NH; Zhang Y
    Pharmacol Res; 2019 Aug; 146():104336. PubMed ID: 31271846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we prevent Parkinson's and Alzheimer's disease?
    Kedar NP
    J Postgrad Med; 2003; 49(3):236-45. PubMed ID: 14597787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
    Di Matteo V; Esposito E
    Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):95-107. PubMed ID: 12769802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
    Belaidi AA; Bush AI
    J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer's Disease and Parkinson's Disease.
    Nakajima A; Ohizumi Y
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress in Parkinson's disease and other neurodegenerative disorders.
    Jenner P
    Pathol Biol (Paris); 1996 Jan; 44(1):57-64. PubMed ID: 8734302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycation in Parkinson's disease and Alzheimer's disease.
    Vicente Miranda H; El-Agnaf OM; Outeiro TF
    Mov Disord; 2016 Jun; 31(6):782-90. PubMed ID: 26946341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences.
    de Andrade Teles RB; Diniz TC; Costa Pinto TC; de Oliveira Júnior RG; Gama E Silva M; de Lavor ÉM; Fernandes AWC; de Oliveira AP; de Almeida Ribeiro FPR; da Silva AAM; Cavalcante TCF; Quintans Júnior LJ; da Silva Almeida JRG
    Oxid Med Cell Longev; 2018; 2018():7043213. PubMed ID: 29861833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An attempt to elucidate the role of iron and zinc ions in development of Alzheimer's and Parkinson's diseases.
    Wojtunik-Kulesza K; Oniszczuk A; Waksmundzka-Hajnos M
    Biomed Pharmacother; 2019 Mar; 111():1277-1289. PubMed ID: 30841441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free radical damage and oxidative stress in Huntington's disease.
    Borlongan CV; Kanning K; Poulos SG; Freeman TB; Cahill DW; Sanberg PR
    J Fla Med Assoc; 1996 May; 83(5):335-41. PubMed ID: 8666972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
    Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
    Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.